Lock in gains for Cytori Therapeautics (CYTX)
Today's Financial News - Posted November 19, 2009
 |
We’re up over 15% from our initial buy price for Cytori Therapeautics (NASDAQ:CYTX). Let’s set a wealth protection stop-loss to ensure modest gains while allowing the share price room to grow.
by Laura Cadden, TodaysFinancialNews.com
Baltimore (TFN): Cytori Therapeutics Inc. (NASDAQ:CYTX) has seen its share price jump on the news that is completed enrollment for an international breast cancer reconstruction study called RESTORE 2.
The company’s Celution®800 System will remove the participant’s own adipose-derived regenerative cells which will then be combined with their fatty tissue for grafting. The hoped-for result would be to restore functional and cosmetic deformities in women who have undergone partial mastectomy for early breast cancer.
This is exciting stuff, but it’s taken us months to hit even 10% gains for our initial buy price of $3.71. (See that Jan. 12 recommendation here.)
If you got in around our levels, I recommend you set a 10% wealth protection stop-loss. We can always buy back in if the price drops lowers.
Next Article: Natural gas hands us monstrous gains!
Be the first to leave a reply.
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down